Famotidine Tablet, Film Coated
Product Images NDC 72865-215

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Famotidine (NDC 72865-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg-100ct (20mg 100ct)

Label for Famotidine Tablets USP 20 mg, film-coated oral tablets. The label indicates it contains 100 tablets and is prescription-only. Manufactured by Ascent Pharmaceuticals, Inc. and labeled for XLCare Pharmaceuticals, Inc. Storage and dispensing instructions are included. The label features the XLcare Pharmaceuticals logo.*

FDA Label Image

20mg-180ct (20mg 180ct)

Label for Famotidine Tablets, USP 20 mg oral film-coated tablets. The bottle contains 180 tablets. The label shows the NDC 72865-214-18 and is manufactured by Ascent Pharmaceuticals, Inc., for XLCare Pharmaceuticals, Inc. Storage instructions and dosage reference are included, with emphasis on prescription use only.*

FDA Label Image

20mg-30ct (20mg 30ct)

The label for Famotidine Tablets USP 20 mg film-coated oral tablets by XL Care Pharmaceuticals, Inc. It indicates an Rx-only product with a package count of 30 tablets. Storage instructions and manufacturing details by Ascent Pharmaceuticals, Inc. and XL Care Pharmaceuticals, Inc. are included. The label also shows the NDC 72865-214-30 and barcode.*

FDA Label Image

20mg-500s.jpg (20mg 500ct)

Label for Famotidine Tablets, USP 20 mg film-coated oral tablets by XLCare Pharmaceuticals, Inc. The label indicates a package size of 500 tablets. It includes storage instructions, manufacturer details, and a barcode. The label also notes this product is Rx only and includes the NDC 72865-214-05.*

FDA Label Image

40mg-100ct (40mg 100ct)

Packaging label for Famotidine Tablets, USP 40 mg, film-coated oral tablets by XLCare Pharmaceuticals, Inc. The label shows the product name, strength, quantity of 100 tablets, NDC 72865-215-01, and manufacturer details for Ascent Pharmaceuticals, Inc. Storage and dispensing instructions are also included.*

FDA Label Image

40mg-180ct (40mg 180ct)

Label for Famotidine Tablets, USP 40 mg film-coated tablets by XL Care Pharmaceuticals Inc. The label shows the product name, strength, NDC code 72865-215-18, and a count of 180 tablets. It includes storage instructions and manufacturer details for Ascent Pharmaceuticals, Inc. and XL Care Pharmaceuticals, Inc.*

FDA Label Image

40mg-30s.jpg (40mg 30ct)

Label for Famotidine Tablets, USP 40 mg oral film-coated tablets by XL Care Pharmaceuticals, Inc. The package contains 30 tablets and is marked Rx only. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), and specifies dispensing in a USP tight, light-resistant container.*

FDA Label Image

40mg-500 (40mg 500ct)

Label for Famotidine Tablets, USP 40 mg by XLCare Pharmaceuticals, Inc. The label indicates the product is prescription only, with a package size of 500 tablets. It includes storage instructions, manufacturer and labeler information, and specifies the film-coated tablet dosage form.*

FDA Label Image

Tab1 (Tab1)

A table titled "Recommended Dosage and Duration of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Normal Renal Function". It lists indications such as active duodenal ulcer, active gastric ulcer, symptomatic nonerosive GERD, and erosive esophagitis, with recommended dosages ranging from 20 mg once daily to 40 mg twice daily, and treatment durations from up to 6 weeks to 12 weeks or as clinically indicated.*

FDA Label Image

Tab2 (Tab2)

Table displaying recommended maximum dosages of Famotidine tablets for adult and pediatric patients 40 kg and greater with moderate and severe renal impairment. Dosages are categorized by indication and creatinine clearance levels, with specific dosage recommendations and footnotes on alternate regimens, dosage adjustments, and considerations for pathological hypersecretory conditions.*

FDA Label Image

Tab3 (Tab3)

Table presenting serum concentrations of famotidine associated with gastric acid reduction in famotidine-treated pediatric and adult patients. It lists EC50 values (ng/mL) for pediatric patients and adults, including healthy adults and adults with upper gastrointestinal bleeding, showing statistical means with standard deviations.*

FDA Label Image

Tab4 (Tab4)

A data table titled 'Patients with Endoscopically Confirmed Healed Duodenal Ulcers' comparing the healing rates at Week 2 and Week 4 for Famotidine 40 mg at bedtime, Famotidine 20 mg twice daily, and placebo. The table presents healing percentages and sample sizes for each group, with statistical significance noted.*

FDA Label Image

Tab5 (Tab5)

A data table titled 'Patients with Endoscopically Confirmed Healed Gastric Ulcers' presenting study results comparing healing rates between Famotidine 40 mg at bedtime and placebo groups in U.S. and International studies at weeks 4, 6, and 8. The table includes sample sizes and indicates statistical significance against placebo.*

FDA Label Image

Tab6 (Tab6)

A data table titled 'Patients with Improvement of Symptomatic GERD (N=376)' showing comparative percentages of improvement at Week 6 among three groups: Famotidine 20 mg twice daily (82%), Famotidine 40 mg at bedtime (69%), and Placebo at bedtime (62%). The table includes sample sizes for each group and notes statistical significance for the 20 mg twice daily group versus placebo.*

FDA Label Image

Tab7 (Tab7)

A data table showing results from a U.S. study on endoscopic healing of erosive esophagitis in 318 patients. It compares healing rates at Week 6 and Week 12 among patients treated with Famotidine 40 mg twice daily, Famotidine 20 mg twice daily, and a placebo taken twice daily.*

FDA Label Image

Tab8 (Tab8)

A table titled 'Patients with Endoscopic Healing of Erosive Esophagitis - International Study (N=440),' comparing healing rates at Weeks 6 and 12 for patients taking Famotidine 40 mg twice daily (N=175), Famotidine 20 mg twice daily (N=93), and Ranitidine 150 mg twice daily (N=172). The table shows percentages of healing at each time point, with a statistical note at Week 12 for Famotidine 40 mg compared to Ranitidine 150 mg.*

FDA Label Image

Struct (Struct)

Chemical structure of famotidine, the active ingredient in the FAMOTIDINE prescription drug. The diagram shows the molecular arrangement including nitro, thiazole, and guanidine groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.